Ferdinand, Keith C.
Dunn, Julia
Nicolay, Claudia
Sam, Flora
Blue, Emily K.
Wang, Hui
Clinical trials referenced in this document:
Documents that mention this clinical trial
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
https://doi.org/10.1186/s12933-023-01775-x
Documents that mention this clinical trial
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
https://doi.org/10.1186/s12933-023-01775-x
Documents that mention this clinical trial
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
https://doi.org/10.1186/s12933-023-01775-x
Documents that mention this clinical trial
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
https://doi.org/10.1186/s12933-023-01775-x
Documents that mention this clinical trial
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
https://doi.org/10.1186/s12933-023-01775-x
Documents that mention this clinical trial
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes
https://doi.org/10.1186/s12933-023-01775-x
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) (Results)
https://doi.org/10.2337/dc20-1473
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 19 December 2022
Accepted: 18 February 2023
First Online: 9 March 2023
Declarations
:
: The AWARD-1, -5, -8, -10, -11, and Ferdinand et al. protocols were approved by research ethics boards for all sites. All participants provided written informed consent.
: All authors have reviewed and approved the content of this manuscript for publication.
: KCF has received consultant fees from Amgen, Sanofi, Boehringer Ingelheim, Novartis, and Medtronic. JD, CN, FS, and EKB are employees and shareholders of Eli Lilly and Company. HW is an employee of TechData Service Company and was contracted by Eli Lilly and Company for this study.